Contact us

If you're interested in partnering with us to improve outcomes, or offering Pomelo as a benefit to your employees or members, we'd love to hear from you.

For candidates interested in joining our team to reinvent maternity and neonatal care, please apply directly to the open roles listed on our Careers page.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Pomelo Care presents data at ACOG 2024 Clinical & Scientific Meeting demonstrating care model impact

Written by
Pomelo Care
Pomelo Care
June 20, 2024
Share this post

Pomelo Care presented data presented at the 2024 American College of Obstetricians and Gynecologists (ACOG) Clinical and Scientific Meeting that showed a 7x increase in depression and anxiety screening and a 2.4x increase in aspirin prophylaxis for preeclampsia prevention in a Medicaid population – impacting two of the leading drivers of maternal morbidity mortality.

Pregnancy-related conditions, including mental health and hypertensive disorders, adversely affect outcomes for women and babies nationwide. Hypertensive disorders in pregnancy are a leading cause of maternal mortality and morbidity in the U.S., affecting 1 in 7 hospital deliveries. Mental health conditions are the leading underlying cause of pregnancy-related deaths in the US. However, fewer than 20% of women self-report symptoms of perinatal depression, highlighting an opportunity for better mental health screening to identify symptoms and initiate treatment to improve outcomes. 

Existing clinical interventions are proven to reduce the risk of preeclampsia by 25% and perinatal depression risk by 40%. Despite these known interventions, patients continue to develop these conditions at alarming rates due to limited and worsening access to maternal care and low rates of these evidence-based interventions, particularly among Medicaid patients. The most recent HEDIS data indicates that only 8.8% of Medicaid patients are screened prenatally for depression. And just 25% or less of pregnant patients with an elevated risk of developing preeclampsia initiate aspirin prophylaxis to reduce preeclampsia risk.

New data from Pomelo demonstrates that its virtual care program effectively scales data-backed interventions to address both preeclampsia and PMAD risk among a Medicaid population. Pomelo’s data showed a:

  • 65% PMAD screening rate, a 7x increase compared to HEDIS data. 
  • 61% prenatal aspirin use rate in patients at elevated risk of preeclampsia, a 2.4x increase compared to the benchmark.
Source: Quantifying Aspirin Prophylaxis Use in Pregnancies in a Medicaid Population at High Risk of Preeclampsia through a Virtual Maternity Care Program, Pomelo Care, 2024
Source: Efficacy of a Virtual Maternity Care Program in Screening for Prenatal Mood and Anxiety Disorders in a Medicaid Population, Pomelo Care, 2024
Share this post

Stay Connected

Stay in the loop - Sign up now to receive the latest news, research, and exciting stories directly to your inbox.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
All clinical services are provided by licensed physicians and clinicians practicing within an independently owned and operated medical practice, Pomelo, P.C. or affiliated professional corporations. Pomelo Care, Inc. does not provide any medical, nursing, or other healthcare provider services.